Modified Release Generic OSD Prescription Pill Manufacturer Dallas Texas



Raphe Pharmaceutique Laboratories in Dallas Texas manufactures Modified release tablets with enteric coating for acidic pills under GMP and FDA compliant laboratory. Each tablet batch undergoes quality control testing for friability, hardness, disintegration, dissolution, melting point, and moisture testing prior to market distribution. Distributors would have access to their ERP QMS software to print product records and monitor production on view only module

Raphe addresses the critical needs of older and younger patients’ populations through the development and manufacturing of a portfolio Generic prescriptions, Topical Treatment products, Oral Solid Dosage Forms and Oral Liquid Dosage Forms. Their products include high-quality branded non-prescription pharmaceutical products, which are distribute to hospitals, long-term care facilities, and retail channels.

Raphe Pharmaceutique addresses the needs of the healthcare system, improve patient’s outcome, eliminates unnecessary costs by increasing product efficiency on treatments. They spiriva manufacturer increase the value of brands and custom manufactured brand by delivering products with unique properties that solve patient’s problems

Raphe demonstrates the benefits of each treatments drug through clinical trials. This approach enables them to establish strong brand reputation with patients, physicians, and retailers. Each of the company’s brands they private label has its own identity, designed to match the relevant target group. They have been successful in building strong brands for physician and healthcare companies providing novel products for customized care.

Their products are sold under company`s brands custom manufactured and private label a large range of dermatological products for the effective management of acne, pigmentations, and hair loss. All clinical therapeutics brands Raphe manufactures for healthcare remdesivir manufacturer companies comes with 100% non-disclosure agreement to protect their buyer`s investment pharmaceutical manufacturer from third party. For more information, contact any of their public retaliation managers for more details.

Leave a Reply

Your email address will not be published. Required fields are marked *